Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients

Rifampicin is a known inducer of the cytochrome P450 (CYP2B6) enzyme, which can lead to a decrease in the concentration of efavirenz. Therefore, we conducted a study to evaluate the effect of daily rifampicin intake on efavirenz 600mg pharmacokinetics and HIV-1 virological suppression. Patients rece...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance 2023-01, Vol.16, p.4659-4666
Main Authors: Wang, Tongtong, Liu, Yingchu, Zhu, Chunyu, Yang, Siyuan, Yang, Di, Xiao, Jiang, Gao, Guiju
Format: Article
Language:English
Subjects:
Analysis
Efavirenz
Enzymes
Ethylenediaminetetraacetic acid
Health aspects
Highly active antiretroviral therapy
hiv/tb
Medical research
Medicine, Experimental
Original Research
Patient compliance
pharmacokinetics
rifampicin
Rifampin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rifampicin is a known inducer of the cytochrome P450 (CYP2B6) enzyme, which can lead to a decrease in the concentration of efavirenz. Therefore, we conducted a study to evaluate the effect of daily rifampicin intake on efavirenz 600mg pharmacokinetics and HIV-1 virological suppression. Patients receiving antiretroviral therapy containing efavirenz (600mg daily), and we collected efavirenz concentration at four visit points: ART day 14 (PK1), ART day 42 (PK2), ART day 140 (PK3), and ART day 336 (PK4), and performed pharmacokinetics analysis. From February 2017 to November 2020, 29 HIV/TB co-infection patients were included. Ninety percent of patients had a concentration of ≥1000ng/mL of efavirenz during the study. All patients had efavirenz C ≥1000ng/mL, 86% patients showed good virology response. Our study shows that the use of rifampicin in HIV/TB co-infection patients does not affect efavirenz drug concentrations, that virological suppression is good and that no efavirenz dose adjustment is required.
ISSN:1178-6973
1178-6973
DOI:10.2147/IDR.S415749